Press Releases

BOSTON , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that  the Company is scheduled to present at
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS in patients receiving 3 or more cycles of therapy with 9.7 months duration of follow-up BOSTON , June 12,